Outlook Therapeutics (OTLK) Other Operating Expenses (2018 - 2026)
Outlook Therapeutics (OTLK) posted quarterly Other Operating Expenses of -$23.6 million for Q1 2026, down 209.29% year-over-year from $21.6 million in Q1 2025, and down 209.29% quarter-over-quarter from $21.6 million in Q1 2025.
Outlook Therapeutics (OTLK) Other Operating Expenses (2018 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has reported Other Operating Expenses for 8 consecutive years, with -$23.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses fell 209.29% year-over-year to -$23.6 million; the TTM figure through Mar 2026 stood at -$23.6 million (up 49.26% YoY), while the FY2025 annual figure was -$70.2 million, down 3.18% from the prior year.
- Other Operating Expenses retreated to -$23.6 million in Q1 2026 per OTLK's latest filing, from $21.6 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $21.6 million in Q1 2025 and bottomed at -$68.0 million in Q3 2024.
- Historically, Other Operating Expenses has averaged -$14.2 million across 4 years, with a median of -$376963.0 in 2022.
- On a YoY basis, Other Operating Expenses climbed as much as 209.29% in 2026 and fell as far as 209.29% in 2026.
- Outlook Therapeutics' Other Operating Expenses stood at -$376963.0 in 2022, then slumped by 17950.19% to -$68.0 million in 2024, then surged by 131.71% to $21.6 million in 2025, then slumped by 209.29% to -$23.6 million in 2026.
- Business Quant data shows OTLK's Other Operating Expenses at -$23.6 million in Q1 2026, $21.6 million in Q1 2025, and -$68.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Outlook Therapeutics | 88.50 Mn | 77.26 Mn | -8,265.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.58 Mn |
| Mar 31, 2025 | 21.57 Mn |
| Sep 30, 2024 | -68.04 Mn |
| Jun 30, 2022 | -376,963.00 |
| Mar 31, 2022 | -343,585.00 |
| Dec 31, 2021 | -162,355.00 |
| Jun 30, 2020 | 104,296.00 |
| Mar 31, 2020 | 423,328.00 |
| Sep 30, 2019 | 8.31 Mn |
| Jun 30, 2019 | 50,927.00 |
| Mar 31, 2019 | 561,735.00 |
| Dec 31, 2018 | 2.35 Mn |